Effects of Cerebrolysin on neuropsychiatric symptoms in Alzheimer's disease: results of a randomized, placebo-controlled trial

被引：0
|
作者：
Alvarez, A. [1 ]
Cacabelos, R. [1 ]
Couceiro, V. [1 ]
Aleixandre, M. [2 ]
Doppler, E. [3 ]
Novak, P. [3 ]
Moessler, H. [3 ]
机构：
[1] EuroEspes Biomed Res Ctr, La Coruna, Spain
[2] Univ Granada, Sch Psychol, Granada, Spain
[3] EVER Neuro Pharma GmbH, Unterach, Austria
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2010年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：72 / 72
页数：1
相关论文
共 50 条
  • [21] Efficacy of FPF 1070 (cerebrolysin) in patients with Alzheimer's disease - A multicentre, randomised, double-blind, placebo-controlled trial
    Xiao, SF
    Yan, HQ
    Yao, PF
    CLINICAL DRUG INVESTIGATION, 2000, 19 (01) : 43 - 53
  • [22] A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
    Turner, R. Scott
    Thomas, Ronald G.
    Craft, Suzanne
    van Dyck, Christopher H.
    Mintzer, Jacobo
    Reynolds, Brigid A.
    Brewer, James B.
    Rissman, Robert A.
    Raman, Rema
    Aisen, Paul S.
    NEUROLOGY, 2015, 85 (16) : 1383 - 1391
  • [23] Cerebrolysin in Patients With Acute Ischemic Stroke in Asia Results of a Double-Blind, Placebo-Controlled Randomized Trial
    Heiss, Wolf-Dieter
    Brainin, Michael
    Bornstein, Natan M.
    Tuomilehto, Jaakko
    Hong, Zhen
    STROKE, 2012, 43 (03) : 630 - 636
  • [24] A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease
    Herrmann, Nathan
    Lanctot, Krista L.
    Rothenburg, Lana S.
    Eryavec, Goran
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2007, 23 (02) : 116 - 119
  • [25] Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial
    Dubois, Bruno
    Lopez-Arrieta, Jesus
    Lipschitz, Stanley
    Triantafyllos, Doskas
    Spiru, Luiza
    Moroz, Svitlana
    Venger, Olena
    Vermersch, Patrick
    Moussy, Alain
    Mansfield, Colin D. D.
    Hermine, Olivier
    Tsolaki, Magda
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)
  • [26] Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
    Bruno Dubois
    Jesús López-Arrieta
    Stanley Lipschitz
    Triantafyllos Doskas
    Luiza Spiru
    Svitlana Moroz
    Olena Venger
    Patrick Vermersch
    Alain Moussy
    Colin D. Mansfield
    Olivier Hermine
    Magda Tsolaki
    Alzheimer's Research & Therapy, 15
  • [27] Effects of memantine on functional communication in moderate Alzheimer's disease: results of a 12-week placebo-controlled trial
    Graham, S.
    Saxton, J.
    Woodward, M.
    Gilchrist, N.
    Potocnik, F.
    Hofbauer, R. K.
    Yu, S. Y.
    Hsu, H.
    Perhach, J. L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S624 - S624
  • [28] Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease
    Hager, Klaus
    Baseman, Alan S.
    Nye, Jeffrey S.
    Brashear, H. Robert
    Han, John
    Sano, Mary
    Davis, Bonnie
    Richards, Henry M.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 391 - 401
  • [29] Methotrexate in Crohn's disease: Results of a randomized, double-blind, placebo-controlled trial
    Arora, S
    Katkov, W
    Cooley, J
    Kemp, JA
    Johnston, DE
    Schapiro, RH
    Podolsky, D
    HEPATO-GASTROENTEROLOGY, 1999, 46 (27) : 1724 - 1729
  • [30] DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled trial - Reply
    Wolkowitz, OM
    Kramer, JH
    Reus, VI
    Yaffe, K
    NEUROLOGY, 2004, 62 (06) : 1030 - 1030
12345